Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Specimen Handling 277 Magnetic Resonance Spectroscopy 228 pembrolizumab 227 Carboplatin 177 Biopsy 168 Cisplatin 164 Nivolumab 157 Cyclophosphamide 143 Paclitaxel 123 Radiotherapy 122 Gemcitabine 115 Bevacizumab 94 durvalumab 91 Dexamethasone 87 Rituximab 79 Oxaliplatin 78 venetoclax 73 atezolizumab 72 Docetaxel 69 Capecitabine 69 Fluorouracil 68 Doxorubicin 67 Etoposide 65 Radiosurgery 62 Ipilimumab 61 Prednisone 60 Cytarabine 60 Radiation 59 Lenalidomide 56 Pemetrexed 55

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × azeliragon × 90 days × Clear all

NCT05986851 2026-03-31

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡